[{"id":"116bdf7a-37b2-4fcf-ba03-fc222544ca83","acronym":"SRF114-101","url":"https://clinicaltrials.gov/study/NCT05635643","created_at":"2022-12-02T15:56:37.453Z","updated_at":"2025-02-25T16:46:24.062Z","phase":"Phase 1","brief_title":"Study of CHS-114 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05635643 - SRF114-101","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tagmokitug (CHS-114)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-05"},{"id":"7d668ceb-425e-4625-a077-dffc5f34f447","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005403","created_at":"2021-08-13T12:53:39.013Z","updated_at":"2024-07-02T16:34:36.863Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab","source_id_and_acronym":"NCT05005403","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 05/04/2026","primary_completion_date":" 05/04/2026","study_txt":" Completion: 05/04/2026","study_completion_date":" 05/04/2026","last_update_posted":"2024-06-10"},{"id":"37756612-b346-458d-bbf9-9e3a38cba018","acronym":"","url":"https://clinicaltrials.gov/study/NCT05935098","created_at":"2023-07-07T14:09:28.288Z","updated_at":"2024-07-02T16:34:59.858Z","phase":"Phase 1","brief_title":"A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05935098","lead_sponsor":"BeiGene","biomarkers":" CCR8","pipe":" | ","alterations":" PD-L1 expression • CCR8 expression","tags":["CCR8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CCR8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-A3055"],"overall_status":"Recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-31"}]